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doi:10.1Objective: Use and operative results of neoadjuvant therapy before major elective resection for primary lung
cancer were examined in the Society of Thoracic Surgeons General Thoracic Surgical Database.
Methods: Lobectomy and pneumonectomy for primary lung cancer were identified in 12,201 patients between
January 2002 and June 2008. After excluding procedures for missing clinical staging or end points; institutions
with more than 10% missing data for clinical stage, discharge mortality, or length of stay; and patients treated
with chemotherapy or radiation for unrelated disease, there remained 5376 resections. Study end points were dis-
charge mortality, length of stay more than 14 days, and major morbidity. Multivariate analysis using propensity
scores stratified into quintiles measured the effect of induction therapy.
Results: In 525 of 5376 procedures (9.8%), chemotherapy (n ¼ 153), radiotherapy (23), or chemoradiotherapy
(349) preceded resection. Compared with resection only, patients receiving induction therapy were younger and
had fewer comorbidities, more reoperative surgery, and higher rates of pneumonectomy. Clinical IIIA-N2 disease
was treated with induction therapy in only 203 of 397 patients (51.1%). Propensity-adjusted rates detected no
difference in discharge mortality, prolonged length of stay, or a composite of major morbidity for patients receiv-
ing induction therapy. Similar results were obtained in a logistic regression model (discharge mortality P¼ .9883;
prolonged hospital stay P ¼ .9710; major morbidity P ¼ .9678).
Conclusion: Less than 10% of all major lung resections for primary carcinoma and just more than half of
all resections for clinical stage IIIA-N2 disease are preceded by neoadjuvant chemotherapy or radiation. This
study does not support concerns over excessive operative risk of induction therapy. (J Thorac Cardiovasc Surg
2010;139:991-6)G
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Distant metastasis is the most common site of treatment fail-
ure after surgical resection for lung cancer. Neoadjuvant
chemotherapy aims to reduce distant and, with the addition
of thoracic radiotherapy in selected patients, locoregional
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The Journal of Thoracic and Cacell lung cancer, although concerns linger about the opera-
tive mortality of pneumonectomy.1 Controversy remains
as to whether patients receiving preoperative therapy are at
greater risk of complications or death as a result, whereas
there is agreement that these patients require careful selec-
tion of their candidacy for additional therapy.1-3
The Society of Thoracic Surgeons (STS) General Tho-
racic Surgery Database (GTSD) was queried to investigate
the effect of induction therapy on operative mortality and
morbidity. We compared patients receiving preoperative
chemotherapy or radiation with those who did not to evalu-
ate the impact of induction therapy on short-term outcomes.
MATERIALS AND METHODS
Major lung resections for primary pulmonary malignancy were collected
from the STS GTSD between January 1, 2002, and June 30, 2008. This pro-
spective database includes patient demographics, medical history, surgical
procedure details, staging, and short-term outcomes. Data were submitted
voluntarily from 112 participating institutions and 463 surgeons during a pe-
riod of significant database expansion using 2 versions of a data-collection
form (http://www.sts.org/sections/stsnationaldatabase/datamanagers/general
thoracicdb/datacollection/index.html). In accordance with the Health
Insurance Portability and Accountability Act of 1996, data were stored and
maintained after annual or biannual harvest at the Duke Clinical Research
Institute, where data completeness and compliance were checked. Incomplete
data were returned to each institution for amendment. The institutional review
boards of all participating institutions agreed to the use of data for quality
improvement research.rdiovascular Surgery c Volume 139, Number 4 991
Abbreviations and Acronyms
CI ¼ confidence interval
FEV1 ¼ forced expiratory volume in 1 second
FVC ¼ forced vital capacity
GTSD ¼ General Thoracic Surgery Database
PLOS ¼ prolonged length of stay
STS ¼ Society of Thoracic Surgeons
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Entry criteria for this study were elective major lung resections, lobec-
tomy, sleeve lobectomy, bilobectomy, or pneumonectomy performed for
primary lung malignancy. Data on timing of neoadjuvant therapy relative
to resection were not collected; however, because intervals of more than 3
months between chemotherapy or radiotherapy and surgical therapy for
this diagnosis are uncommon, we assumed that therapy before resection
had the purpose of induction. The assignment of clinical stage is critical
to the indication for neoadjuvant therapy and influences the type of resec-
tion; however, this variable was not routinely collected by several of the da-
tabase participants. For this reason, we excluded from our study all
procedures done at institutions with less than 90% completeness for clinical
staging. Among 29 database participants reporting more than 100 patients,
15 had missing clinical stage data in more than 10% of procedures; the par-
ticipant with the largest number of entries reported clinical stage in only
10% of procedures. The consort diagram (Figure 1) displays patient popu-
lation and excluded operations. Given the present database maturity and the
low rates of 30-day or hospital mortality, prolonged length of stay (PLOS),
and composite rates of morbidity, we combined patients receiving either
chemotherapy or radiation or both into the induction group. The character-
istics of the resultant patient population are reported in Table 1.
Descriptive and Outcome Variables
Preoperative risk factors, procedures, andpostoperative events are defined
by the STS GTSD. We examined 3 outcomes: discharge mortality, hospital
stay more than 14 days, and a composite of major postoperative events. Dis-
charge mortality was defined as occurring during the same hospitalization.
PLOS greater than 14 days was found to be a surrogate for operative risk
in a recent study of the STSGTSD.4 The composite of events includedmajor
postoperative complications (pneumonia, initial vent support>48 hours, re-
intubation, adult respiratory distress syndrome, tracheostomy, empyema,
sepsis, bronchopleural fistula, myocardial infarction, deep vein thrombosis,
bleeding requiring reoperation, and new central neurologic event).
Handling of Missing Variables
Model covariates with high rates of missing data were percent of pre-
dicted forced expiratory volume in 1 second (FEV1; 10.9%missing), forced
vital capacity (FVC; 18.7% missing), and body mass index (8.15% miss-
ing). The remaining covariates were missing less than 5%. For variables
missing more than 10%, an indicator for ‘‘missing’’ was included in the
model. This strategy was used for FEV1 and FVC. For body mass index,
missing data were imputed to the gender-specific median of non-missing
values. For other continuous variables, the missing value was imputed to
the overall median. Finally, for categoric variables, the missing value was
imputed to the most common value.
Statistical Analysis
Summary statistics included percentages for categoric variables and me-
dians for continuous variables. The Pearson chi-square test was used for
comparing all categoric variables, and the Wilcoxon rank-sum test was
used for comparing all the continuous or ordinal variables.992 The Journal of Thoracic and Cardiovascular SurgPropensity score stratification was used to adjust for differences in co-
morbidities, functional status, clinical stage, operative procedure, and oper-
ative approach. Logistic regression estimated the probability of undergoing
resection with preoperative induction therapy. Covariates in this logistic
model to estimate propensity score were age, body mass index, gender,
race, FEV1 predicted, FVC predicted, tobacco use, time since last cigarette,
pack years, hypertension, steroid use, congestive heart failure, coronary ar-
tery disease, peripheral vascular disease, cerebrovascular disease, diabetes
mellitus, renal insufficiency, thoracic reoperation, clinical stage, American
Society of Anesthesiology class, Zubrod score, type of procedure, and op-
erative approach. Although we considered an earlier report from the STS
GTSD on carbon monoxide diffusion capacity as a predictor of pulmonary
complications,5 diffusion capacity of the lung for carbon monoxide was ex-
cluded from the multivariate analysis because the rate of missing data was
high (27.6%) and it was nonsignificant in the univariate analysis of unad-
justed rates. Before propensity stratification, 32 of 52 covariates were signif-
icantly different between the groups with and without induction therapy. By
using propensity scoring, resections were stratified in 5 strata; only 3 cova-
riates, FEV1 predicted, FVC predicted, and clinical T1-3N2, remained sig-
nificantly different after stratification. Tables E1 to E3 show the observed
event rates along with 95% confidence interval (CI) of study end points
(discharge mortality, PLOS, and the composite of major complications)
by 5 subgroups based on propensity quintiles.
We used a multivariate logistic regression model to evaluate the associ-
ation between induction therapy and our study end points adjusting for pro-
pensity strata. The variables offered to this multivariate model were
treatment (induction therapy), propensity stratum, included interaction
terms of treatment and stratum, and 3 covariates that remained significantly
different after stratification. These 3 covariates were dichotomous indicator
variables of missing of FEV predicted, missing of FVC predicted, and clin-
ical stage: T1,2,3-N2.
All P values were calculated by comparing only non-missing values.
The Bonferroni correction was applied to the 21 postoperative events listed
in Table 2, and the significance level was established as .05/21 ¼ .00238.
Otherwise, the significance level was assessed at the .05 alpha level. All
analyses were conducted using SAS 8.2 or SAS 9.2 (SAS Institute Inc,
Cary, NC).
RESULTS
Of 5376 operations in the study group, 4851 were resec-
tions without and 525 with (9.8%) preoperative therapy,
the latter consisting of chemotherapy (n ¼ 153), radiother-
apy (23), or chemoradiotherapy (349). The characteristics
of the resection only and induction groups are compared in
Table 1. Patients receiving induction were younger, more
likely of Hispanic or Asian race, less likely recent smokers,
more symptomatic, and more commonly in American Soci-
ety of Anesthesiology class III. Induction patients had
a higher FVC and a lower rate of hypertension, diabetes, cor-
onary artery disease, and congestive heart failure. Resec-
tions after induction were furthermore 3 times as likely as
thoracic reoperations (10.3% vs 3.5%, P< .0001).
Induction therapy was applied in less than 10% of all re-
sections: in 3.1% (118/3790) of stage I disease, 17.6% (108/
613) of stage II disease, 49.3% (220/446) of stage IIIA dis-
ease, and 29.9% (46/154) of stage IIIB disease. Of 397 re-
sections for clinical IIIA-N2 disease, 203 (51.1%) were
preceded by neoadjuvant therapy. Concurrent mediastino-
scopy was performed in 14% (56/397) of these procedures.
In the induction therapy group with clinical N2, 80%ery c April 2010
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FIGURE1. Consort diagram describing the exclusion criteria and resultant
study population.
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treatment strategies in patients with stage II and III disease.
Induction therapy preceded resection in only a minority of
procedures for clinical stage II disease and less than half
of all patients with stage III disease. As shown in Table 3,
induction therapy was associated with higher rates of pneu-
monectomy, sleeve, and bilobectomy, as well as a preference
for thoracotomy over thoracoscopy. The institution-specific
separation of treatment strategies as shown in Figure E1
shows no preference for either resection only or multimodal-
ity therapy in centers with more than 5 resections. Clinical
and pathologic N2 were widely divergent, as detailed in
Table E4. Only 50% of resections without neoadjuvant
therapy for clinical T1-3N2 disease were determined to
have pathologic N2, whereas 42% receiving induction had
retained N2 status in the final specimen.
Table 2 shows the univariate analysis of postoperative
events. Patients in the induction group were more likely to
require bronchoscopy for atelectasis and had higher rates
of wound infection, recurrent laryngeal nerve injury, and ei-
ther intra- or postoperative blood transfusions. The rate of
bronchopleural fistula was approximately 3-fold higher;
this difference was not significant in a comparison limited
to clinical IIIA-N2 tumors. There was no difference in the
rate of pneumonia, empyema, sepsis, or cardiovascular com-The Journal of Thoracic and Caplications. There was no significant difference in the 30-day
mortality or discharge mortality. Neither median nor mean
length of stay was longer in the induction group (resection
only vs induction, 6.84 vs 6.85 days; P ¼ .0551), and there
was no significant difference in the rate of PLOS (7.2% in
the resection only group and 8.2% in the induction group,
P ¼ .311). Morbidity as a composite of major pulmonary
and cardiovascular complications showed no significant in-
crease in the group of patients treated with preoperative che-
motherapy or radiation.
Propensity-adjusted mortality rates were 1.71% (0.61%–
2.82%) for patients with induction therapy versus 1.67%
(1.31%–2.03%) for patients without induction therapy (dif-
ference 0.69%; 95% CI, 3.53% to 4.90%; P ¼ .63).
Results were similar after including treatment (induction
therapy), propensity stratum, interaction of treatment and
propensity stratum, dichotomous indicator variables for
missing FEV1 predicted, missing FVC predicted, and clini-
cal stage IIIA(N2) in a logistic regression model (P ¼
.9883). For the end point length of stay greater than 14
days, the propensity-adjusted occurrence rate was 5.90%
(3.89%–7.92%) for patients with induction and 6.89%
(6.17%–7.60%) for patients without induction therapy (dif-
ference0.99%; 95% CI,4.79% to 2.81%; P ¼ .21). The
logistic regression model showed no significant prolonga-
tion of stay after resections following induction therapy (P
¼ .9710). For the end point composite of major morbidity,
the propensity-adjusted rate was 10.5% (7.86%–13.1%)
for induction therapy and 9.21% (8.40%–10.0%) for resec-
tion alone (difference1.36%; 95% CI,4.69% to 1.97%;
P ¼ .31). The logistic regression model resulted in a similar
outcome (P ¼ .9678). Risk-adjusted analysis did not detect
a difference in discharge mortality, PLOS, or major morbid-
ity for patients receiving induction therapy.
DISCUSSION
In an era when the benefits of postoperative adjuvant che-
motherapy have become firmly established, a survey of ma-
jor lung resection for cancer in the STS GTSD finds a low
rate of neoadjuvant therapy, even for clinical stages with
high distant and regional failure rates, and low operative
risk whether or not induction therapy is administered. Al-
though neoadjuvant therapy is well tolerated, it is not widely
used for lung cancer among STS database participants. As
shown in a previous report from the STS GTSD,6 the oper-
ative results of patients in the GTSD compare favorably to
those reported in other large databases. This difference
may be related to the higher level of training and experience
in the surgeons participating in the GTSD. The voluntary
structure of this database may allow for selective reporting
and restrict generalization from this study to the wider tho-
racic surgical practice in North America; however, we do
not expect a higher rate of neoadjuvant therapy in other
multi-institutional thoracic databases.rdiovascular Surgery c Volume 139, Number 4 993
TABLE 1. Patient characteristics and comorbidities
Resection
N ¼ 4851
Induction therapy
N ¼ 525 P value
Age (median) 68 y 63 y <.0001
Gender
Male 49.52% 49.90% .8655
Race .0119
Caucasian 85.16% 85.71%
Black 8.70% 6.10%
Hispanic 1.63% 2.48%
Asian 1.92% 2.29%
Native American 0.02% 0.19%
Missing/other/mixed 2.58% 3.23%
Cigarette use 96.27% 95.87% .7882
Missing 0.05% 0.21%
Pack y (median) 40 40 .8307
Missing 2.21% 1.51%
Time since last cigarette <.0001
0–14 d 22.90% 19.05%
14 d to 1 mo 4.76% 3.24%
1–12 mo 9.92% 24.38%
>12 mo 47.99% 42.86%
Missing 1.22% 0.76%
Zubrod score .0004
0 46.28% 38.10%
1 44.26% 46.48%
2 4.97% 7.43%
3 0.66% 1.14%
4 0.02% 0.19%
Missing 3.81% 6.67%
ASA category .0019
I 3.15% 0.57%
II 19.85% 14.86%
III 60.85% 67.62%
IV–V 11.67% 11.62%
Missing 4.41% 5.33%
Body mass index (median) 26.42 25.88 .0540
Missing 7.73% 12.00%
PFTs (mean of% predicted)
FVC 86.23% 88.56% .0118
Missing 18.52% 20.57%
FEV1 79.59% 80.94% .3196
Missing 11.21% 8.00%
DLCO 73.52% 71.93% .1266
Missing 28.53% 19.24%
Comorbidities:
Hypertension 57.14% 37.52% <.0001
Missing 0.14% 0.57%
Steroid use 3.38% 2.86% .5321
Missing 0.68% 0.95%
Congestive heart failure 3.17% 1.52% .0358
Missing 0.68% 0.76%
Coronary artery disease 21.71% 14.86% .0003
Missing 0.52% 0.95%
Peripheral vascular disease 9.83% 4.95% .0003
Missing 0.56% 0.76%
Cerebrovascular event 11.86% 12.00% .2317
Missing 1.67% 1.14%
TABLE 1. Continued
Resection
N ¼ 4851
Induction therapy
N ¼ 525 P value
Diabetes 14.74% 9.71% .0017
Missing 0.02% 0.00%
Renal insufficiency .1507
Creatinine>2 2.37% 1.71%
Dialysis 0.54% 0.00%
Missing 0.39% 0.19%
Thoracic reoperation 3.46% 10.29% <.0001
Missing 0.56% 0.00%
ASA,American Society of Anesthesiology; PFT, pulmonary function test; FVC, forced
vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, carbon monoxide
diffusing capacity. Variables in bold font denote a significant difference between the
groups (P< .05).
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cer remains controversial, although small randomized trials
demonstrated a survival benefit7,8 and a meta-analysis
concurred.9 Other studies failed to confirm improvedTABLE 2. Postoperative events and outcomes in resection and
induction groups
Postoperative event
Resection
(N ¼ 4851)
No. of resections
(%)
Induction therapy
(N ¼ 525)
No. of resections
(%)
P
value
Bronchoscopy 162 (3.34%) 33 (6.29%) .0033
Mechanical ventilation
>48 h
35 (0.72%) 3 (0.57%) .5711
Reintubation 186 (3.83%) 22 (4.19%) .9470
Tracheostomy 62 (1.28%) 7 (1.33%) .8759
ARDS 68 (1.40%) 9 (1.71%) .7793
Pneumonia 212 (4.37%) 25 (4.76%) .9331
Empyema 23 (0.47%) 2 (0.38%) .6587
Sepsis 35 (0.72%) 1 (0.19%) .1206
Wound infection 12 (0.25%) 7 (1.33%) .0002*
Bronchopleural fistula 17 (0.35%) 5 (0.95%) .0673
Recurrent laryngeal
nerve injury
21 (0.43%) 10 (1.90%) <.0001*
Atrial arrhythmia 558 (11.5%) 61 (11.62%) .4127
Myocardial infarction 21 (0.43%) 2 (0.38%) .7522
Cerebrovascular event 33 (0.68%) 4 (0.76%) .9852
Deep venous
thrombosis
22 (0.45%) 1 (0.19%) .3209
Blood transfusion 384 (7.92%) 93 (17.71%) <.0001*
Postoperative
outcomes:
30-d mortality 89 (1.83%) 12 (2.29%) .4687
Discharge mortality 81 (1.67%) 9 (1.71%) .9398
Median length
of stay (d)
5 SD 6.23 5 SD 5.76 .0551
Length of stay>14 d 334 (6.89%) 31 (5.90%) .3963
Composite of major
morbidity
447 (9.21%) 55 (10.5%) .3347
ARDS, Adult respiratory distress syndrome; SD, standard deviation. Variables in bold
font denote a significant difference between the groups (P< .05). P values marked
with * remain significant after Bonferroni correction.
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institutional, prospective randomized studies13,14 reported
increased risks of pneumonectomy after neoadjuvant ther-
apy. Thus, a cautious attitude is appropriate toward induc-
tion therapy in stages that are not locally advanced.
However, in stage IIIA, systemic disease poses a far greater
threat even after complete resection; thus, neoadjuvant
therapy should offer its greatest potential gain in this set-
ting as acknowledged in clinical guidelines published by
the American College of Chest Physicians in 2003.15 The
observation that surgical resection is the first treatment of
approximately half of all preoperatively recognized stage
IIIA lung cancers is therefore surprising. A difference in
the relative frequency of pathologic N2 status is expected
for clinical N2 disease treated or not with induction; the ef-
fect of downstaging by chemoradiation, however, would be
expected to exceed the difference of 8.2% noted in Table
E4. The infrequent use of neoadjuvant therapy in IIIA-N2
disease in this study does not seem to relate to surgical vol-TABLE 3. Extent of resection and surgical approach for resection and ind
Resection (N ¼ 4851)
No. of resections (%)
Extent of resection
Lobectomy 4299 (88.62%)
Sleeve lobectomy 90 (1.86%)
Bilobectomy 201 (4.14%)
Pneumonectomy, standard 199 (4.10%)
Pneumonectomy,
intrapericardial
62 (1.28%)
Surgical approach
Thoracotomy 3289 (67.80%)
Thoracoscopy 1438 (29.64%)
Other 124 (2.56%)
The Journal of Thoracic and Caume; there was no correlation between the number of pa-
tients with IIIA-N2 treated per participant site and the
rate of induction therapy. The frequency of preoperative
chemotherapy or radiation may have been underestimated
if information on treatment delivered outside the participat-
ing center was unavailable and the respective data fields
were left unchecked. Clinical staging inaccuracies were ob-
served, but their impact on the use of neoadjuvant therapy
is uncertain.
Among patients selected for resection by surgeons partici-
pating in the STS GTSD, preoperative chemotherapy and
combined chemoradiotherapy were well tolerated. The dif-
ferences in age, comorbid conditions, and lung function
seen in the univariate analysis of preoperative variables be-
tween resection and multimodality therapy suggests that
candidates were selected for neoadjuvant therapy and that
this selection was successful in limiting operative death, ma-
jor morbidity, and differences in length of hospital stay.
However, the unadjusted rates of certain postoperative
events were increased after induction therapy; bronchopleu-
ral fistula, for example, was approximately 3 times as com-
mon (albeit still rare). Thus, induction therapy may be
associated with specific nonlethal operative risks. Because
these data originate from a recently inaugurated database
with limited, but growing participation, they may not be rep-
resentative of selection standards in North American institu-
tions treating lung cancer.
Study Limitations
There are important limitations to our study. The STS
GTSD is unaudited; thus data entry and important variables,
among them clinical stage, discharge mortality, and postop-
erative events, have not been checked for accuracy. The da-
tabase is not designed to record treatment other than surgical
resection and did not provide intention-to-treat analysis of
patients treated with neoadjuvant therapy but not proceeding
to resection. The operative mortality for induction with cis-
platin and etoposide plus concurrent thoracic radiotherapy in
the Southwestern Oncology Group study 8805, for example,uction procedures
Induction therapy (N ¼ 525)
No. of resections (%) P value
<.0001
399 (76.00%)
27 (5.14%)
22 (4.19%)
60 (11.43%)
17 (3.24%)
<.0001
458 (87.24%)
56 (10.67%)
11 (2.10%)
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10%.13 Details about the regimens of chemotherapy or radi-
ation, or completeness of therapy that may expose differ-
ences in the implementation of induction therapy among
participating centers were unavailable. Our criteria for ex-
clusion of database participants led to loss of large numbers
of procedures and may have selectively excluded qualita-
tively different patients or procedures; we considered a com-
parison of included and excluded procedures, but the
amount of missing data would prevent a meaningful
comparison. Finally, the conclusions of this study rest on ac-
curate clinical staging. Although we found major discrep-
ancies between clinical and pathologic staging in N2
disease, these differences remain unexplained and are diffi-
cult to resolve after data submission. A surgeon-initiated
mandatory protocol for clinical staging before resection
did not exist previously to address the unacceptably high
rate of missing clinical staging. Medicare’s 2009 Physician
Quality Reporting Initiative, however, contains the record-
ing of clinical staging before treatment for lung cancer
(http://www.cms.hhs.gov/PQRI/Downloads/2009_PQRI_
MeasuresList_030409.pdf). This reporting requirement
was added at the suggestion of the STS and should
reduce the missing data problem for clinical staging. The
STS GTSD has also recently defined more stringent data
quality criteria for submission.
CONCLUSIONS
The STSGTSD presents a potentially powerful way to ad-
dress clinical questions for which clinical trials have not yet
been or may never be designed. Many STS surgeons may be
skeptical of the efficacy of induction therapy for IIIA disease
or fearful of excessive postoperative morbidity. We cannot
answer the first question, but our study suggests there is
not excessive morbidity after induction therapy. Prospec-
tively collected data from multiple centers can be a robust
tool to evaluate clinical questions. As the GTSD continues
to grow both in procedures and number of participants
with further refinement of collected variables, its usefulness
as a research tool is expected to increase.996 The Journal of Thoracic and Cardiovascular SurgReferences
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FIGURE E1. Initial treatment modalities in clinical T1-3N2 patients by participant site at sites with more than T1-3N2 resections.
TABLE E1. Discharge mortality rate by propensity score quintiles
Resection Induction therapy
N Mortality rate (95% CI) N Mortality rate (95% CI)
Quintile 1 1065 1.69% (0.92%–2.46%) 10 0% (0%–0%)
Quintile 2 1054 1.71% (0.93%–2.49%) 21 4.76% (0%–13.87%)
Quintile 3 1043 1.92% (1.09%–2.75%) 33 3.03% (0%–8.88%)
Quintile 4 997 1.60% (0.82%–2.38%) 78 2.56% (0%–6.07%)
Quintile 5 692 1.30% (0.46%–2.14%) 383 1.31% (0.17%–2.44%)
CI, Confidence interval.
TABLE E2. Hospital stay greater than 14 days by propensity score quintiles
Resection Induction therapy
N PLOS>14 d rate (95% CI) N PLOS>14 d rate (95% CI)
Quintile 1 1065 6.10% (4.67%–7.54%) 10 0% (0%–0%)
Quintile 2 1054 5.88% (4.46%–7.30%) 21 9.52% (0%–22.08%)
Quintile 3 1043 6.14% (4.68%–7.59%) 33 6.06% (0%–14.20%)
Quintile 4 997 7.32% (5.71%–8.94%) 78 7.69% (1.78%–13.61%)
Quintile 5 692 10.12% (7.87%–12.36%) 383 5.48% (3.20%–7.76%)
PLOS, Prolonged length of stay; CI, confidence interval.
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TABLE E3. Major morbidity rate by propensity score quintiles
Resection Induction therapy
N Morbidity rate (95% CI) N Morbidity rate (95% CI)
Quintile 1 1065 8.45% (6.78%–10.12%) 10 0% (0.00%–0.00%)
Quintile 2 1054 7.21% (5.65%–8.77%) 21 14.29% (0.00%–29.25%)
Quintile 3 1043 9.97% (8.15%–11.79%) 33 6.06% (0.00%–14.20%)
Quintile 4 997 10.63% (8.72%–12.55%) 78 10.26% (3.52%–16.99%)
Quintile 5 692 10.26% (8.00%–12.52%) 383 10.97% (7.84%–14.10%)
CI, Confidence interval.
TABLE E4. Pathologic nodal status of patients with clinical T1-3, N2
Pathologic
N-status
Resection (N ¼ 194)
No. of resections (%)
Induction therapy (N ¼ 203)
No. of resections (%)
N0 61 (31.4%) 75 (37.0%)
N1 27 (13.9%) 27 (13.3%)
N2 97 (50.0%) 85 (41.8%)
N3 0 (0.0%) 1 (0.5%)
Nx 0 (0.0%) 4 (2.0%)
Missing 9 (4.7%) 11 (5.4%)
General Thoracic Surgery Evans III et al
996.e2 The Journal of Thoracic and Cardiovascular Surgery c April 2010
G
T
S
